| Ticker Symbol: | CRIS |
|---|---|
| Exchange: | NASD |
| Contact Info: | 45 Moulton Street Cambridge MA 02138 617 503-6500 |
| CEO/President: | Daniel R. Passeri |
| Industry: | Medical - Biomedical / Standard Industry Code: 2836 |
| Description: | Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis\' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. |
| Shares Outstanding: | 63,430 (000) | Market Value: | 50,750 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 50.87% | Number of Inst.Shareholders: | 9.06% |
| Last Quarter Sales: | 0.09 ($Mil.) | Last Quarter Net Income: | -4.57 ($Mil.) |
| Last Quarter EPS: | -0.07 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.08 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +12.60 | 58.23 | |
| GILEAD SCIENCES | -1.00 | 46.92 | |
| CELGENE CP | -10.00 | 58.86 | |
| BIOGEN IDEC INC | -31.90 | 43.52 | |
| AMYLIN PHARMA I | -85.70 | 6.41 |
